Orbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis
暂无分享,去创建一个
F. Latrofa | M. Marinò | G. Lanzolla | I. Ionni | M. Marinò | I. Ionni | G. Lanzolla | A. Sframeli | F. Latrofa | R. Rocchi | C. Marcocci | R. Rocchi | C. Marcocci | A. Sframeli | Michele Marinò | C. Marcocci
[1] W. Wiersinga,et al. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy , 1997, Clinical endocrinology.
[2] L. Bartalena,et al. Prevalence and natural history of Graves’ orbitopathy in the XXI century , 2013, Journal of Endocrinological Investigation.
[3] T. Sullivan. Vascular Anomalies of the Orbit--A Reappraisal. , 2018, Asia-Pacific journal of ophthalmology.
[4] W. Wiersinga,et al. The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy , 2016, European Thyroid Journal.
[5] C. Marcocci,et al. Mechanistic Pathways of Selenium in the Treatment of Graves’ Disease and Graves’ Orbitopathy , 2018, Hormone and Metabolic Research.
[6] L. Hegedüs,et al. Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement , 2017, Orphanet Journal of Rare Diseases.
[7] L. Chiovato,et al. Graves’-like orbitopathy: do not forget IgG4-related disease , 2014, Journal of Endocrinological Investigation.
[8] G. Rose,et al. Consensus on Diagnostic Criteria of Idiopathic Orbital Inflammation Using a Modified Delphi Approach , 2017, JAMA ophthalmology.
[9] P. Dolman. Evaluating Graves' orbitopathy. , 2012, Best practice & research. Clinical endocrinology & metabolism.
[10] M. Stan,et al. MANAGEMENT OF ENDOCRINE DISEASE: Rituximab therapy for Graves' orbitopathy - lessons from randomized control trials. , 2017, European journal of endocrinology.
[11] L. Bartalena,et al. Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? , 2017, Journal of Endocrinological Investigation.
[12] S. Heegaard,et al. Orbital lymphoma. , 2019, Survey of ophthalmology.
[13] C. Marcocci,et al. Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial , 2018, Journal of Endocrinological Investigation.
[14] Terry J. Smith,et al. Teprotumumab for Thyroid‐Associated Ophthalmopathy , 2017, The New England journal of medicine.
[15] M. Nardi,et al. Antioxidant Actions of Selenium in Orbital Fibroblasts: A Basis for the Effects of Selenium in Graves' Orbitopathy. , 2017, Thyroid : official journal of the American Thyroid Association.
[16] J. Goyal,et al. Limited Wegener's granulomatosis of the orbit: a case study and review of literature , 2005, Eye.
[17] M. Nardi,et al. Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? , 2017, Journal of Endocrinological Investigation.
[18] W. Wiersinga,et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. , 2018, The lancet. Diabetes & endocrinology.
[19] P. Rubin,et al. Idiopathic orbital inflammation: distribution, clinical features, and treatment outcome. , 2003, Archives of ophthalmology.
[20] M. Nardi,et al. Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy , 2018, JAMA ophthalmology.
[21] Terry J. Smith,et al. Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy. , 2018, Endocrine reviews.
[22] A. Weber,et al. Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. , 1999, Radiologic clinics of North America.
[23] L. Newman,et al. Medical progress : Sarcoidosis , 1997 .
[24] A. Sepahdari,et al. Orbital inflammatory disease: Pictorial review and differential diagnosis. , 2014, World journal of radiology.
[25] M. Nardi,et al. Selenium and the course of mild Graves' orbitopathy. , 2011, The New England journal of medicine.
[26] A. Suri,et al. Sphenoid wing inflammatory pseudotumor mimicking a clinoidal meningioma: case report and review of the literature. , 2008, Surgical neurology.
[27] Vikram Deshpande,et al. IgG4-Related Disease , 2013, International journal of rheumatology.
[28] C. Marcocci,et al. A Case of Unilateral Dermopathy Possibly Related to Graves’ Disease , 2019, European Thyroid Journal.
[29] T. McCulley,et al. Orbital Disease in Neuro-Ophthalmology. , 2010, Neurologic clinics.
[30] M. Marinov,et al. [Orbital lymphoma]. , 2009, Khirurgiia.
[31] 陶仲为. Sarcoidosis , 2009 .
[32] C. Marcocci,et al. Studies on the occurrence of ophthalmopathy in Graves' disease. , 1989, Acta endocrinologica.
[33] M. Nardi,et al. Role of the underlying thyroid disease on the phenotype of Graves' orbitopathy in a tertiary referral center. , 2015, Thyroid : official journal of the American Thyroid Association.
[34] M. Nardi,et al. Antioxidant effects of β-carotene, but not of retinol and vitamin E, in orbital fibroblasts from patients with Graves’ orbitopathy (GO) , 2018, Journal of Endocrinological Investigation.
[35] L. Chiovato,et al. Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy , 2018, Journal of Endocrinological Investigation.
[36] S. Hickman. Optic Perineuritis , 2016, Current Neurology and Neuroscience Reports.
[37] A. Weber,et al. Pseudotumor of the orbit. Clinical, pathologic, and radiologic evaluation. , 1999, Radiologic clinics of North America.
[38] J. V. Pérez-Moreiras,et al. Treatment of Active Corticosteroid-Resistant Graves’ Orbitopathy , 2014, Ophthalmic plastic and reconstructive surgery.
[39] M. Nardi,et al. Action of three bioavailable antioxidants in orbital fibroblasts from patients with Graves’ orbitopathy (GO): a new frontier for GO treatment? , 2018, Journal of Endocrinological Investigation.
[40] R. Nugent,et al. Optic nerve sheath meningiomas. , 2003, Ophthalmology.
[41] M. Nardi,et al. Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy , 2015, Journal of Endocrinological Investigation.
[42] Yağmur Seda Yeşiltaş,et al. Idiopathic Orbital Inflammation: Review of Literature and New Advances , 2018, Middle East African journal of ophthalmology.
[43] J. Stone,et al. IgG4-related disease. , 2012, The New England journal of medicine.
[44] L. Chiovato,et al. Role of thyroglobulin in the pathogenesis of Graves’ ophthalmopathy: The hypothesis of Kriss revisited , 2004, Journal of endocrinological investigation.
[45] B. Schoser,et al. “Orbiting around” the orbital myositis: clinical features, differential diagnosis and therapy , 2015, Journal of Neurology.
[46] Z. Ding,et al. Idiopathic orbital pseudotumour. , 2011, Clinical radiology.
[47] M. Rotondi,et al. DIAGNOSIS OF ENDOCRINE DISEASE: IgG4-related thyroid autoimmune disease. , 2019, European journal of endocrinology.
[48] R. Bahn. Current Insights into the Pathogenesis of Graves’ Ophthalmopathy , 2015, Hormone and Metabolic Research.
[49] C. Shields,et al. Overview of benign and malignant lacrimal gland tumors , 2018, Current opinion in ophthalmology.
[50] E. Bonfá,et al. Sjögren’s syndrome and systemic lupus erythematosus: links and risks , 2019, Open access rheumatology : research and reviews.
[51] J. Rosenbaum,et al. Orbital inflammatory disease. , 2008, Seminars in arthritis and rheumatism.
[52] Christine O Menias,et al. Inflammatory pseudotumor: the great mimicker. , 2012, AJR. American journal of roentgenology.
[53] C. Marcocci,et al. Management of Graves' ophthalmopathy: reality and perspectives. , 2000, Endocrine reviews.
[54] L. Sánchez,et al. [Idiopathic orbital myositis]. , 1999, Medicina clinica.
[55] C. Marcocci,et al. Selenium in Graves Hyperthyroidism and Orbitopathy. , 2018, Ophthalmic plastic and reconstructive surgery.
[56] Jianhua Yan,et al. Idiopathic Orbital Myositis , 2014, The Journal of craniofacial surgery.